Editas Medicine Inc (EDIT)
5.625
-0.26
(-4.50%)
USD |
NASDAQ |
May 17, 16:00
5.625
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Research and Development Expense (Quarterly): 48.79M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 48.79M |
| December 31, 2023 | 69.56M |
| September 30, 2023 | 40.51M |
| June 30, 2023 | 29.78M |
| March 31, 2023 | 37.80M |
| December 31, 2022 | 52.00M |
| September 30, 2022 | 41.33M |
| June 30, 2022 | 43.66M |
| March 31, 2022 | 37.98M |
| December 31, 2021 | 37.55M |
| September 30, 2021 | 29.26M |
| June 30, 2021 | 33.75M |
| March 31, 2021 | 41.94M |
| December 31, 2020 | 61.50M |
| September 30, 2020 | 33.92M |
| June 30, 2020 | 28.01M |
| March 31, 2020 | 34.57M |
| December 31, 2019 | 34.79M |
| September 30, 2019 | 22.70M |
| Date | Value |
|---|---|
| June 30, 2019 | 23.56M |
| March 31, 2019 | 15.84M |
| December 31, 2018 | 19.19M |
| September 30, 2018 | 17.44M |
| June 30, 2018 | 32.72M |
| March 31, 2018 | 21.30M |
| December 31, 2017 | 26.42M |
| September 30, 2017 | 20.40M |
| June 30, 2017 | 17.32M |
| March 31, 2017 | 19.02M |
| December 31, 2016 | 26.84M |
| September 30, 2016 | 10.83M |
| June 30, 2016 | 10.43M |
| March 31, 2016 | 8.882M |
| December 31, 2015 | 5.826M |
| September 30, 2015 | 3.85M |
| June 30, 2015 | 7.282M |
| March 31, 2015 | 1.888M |
| December 31, 2014 | 2.395M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
22.70M
Minimum
Sep 2019
69.56M
Maximum
Dec 2023
39.15M
Average
37.68M
Median
Research and Development Expense (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | 789.10M |
| Bristol-Myers Squibb Co | 2.695B |
| Regeneron Pharmaceuticals Inc | 1.248B |
| Cabaletta Bio Inc | 21.95M |
| Oragenics Inc | 11.04M |